» Articles » PMID: 32875464

Taiwan Society of Colon and Rectal Surgeons (TSCRS) Consensus for Cytoreduction Selection in Metastatic Colorectal Cancer

Overview
Journal Ann Surg Oncol
Publisher Springer
Specialty Oncology
Date 2020 Sep 3
PMID 32875464
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Taiwan has witnessed a surge in the incidence of colorectal cancer (CRC), of which 40-60% metastasize. Continuous updating of cytoreductive strategies in metastatic CRC (mCRC) has contributed to median overall survival reaching 40 months. In this changing scenario, to standardize the approaches across Taiwan, a group of experts from the Taiwan Society of Colon and Rectal Surgeons (TSCRS) convened to establish evidence- and opinion-based recommendations for defining the criteria of "resectability" in mCRC.

Methods: Over the course of one-on-one consultations, lasting 30-40 min each, with 30 medical specialists (19 colorectal surgeons, 4 general surgeons, and 7 medical oncologists) from 16 hospitals in Taiwan followed by a 2-h meeting with 8 physician experts (3 general surgeons, 4 colorectal surgeons, and 1 thoracic surgeon), 12 key questions on cytoreduction were addressed. This was further contextualized based on published literature.

Results: The final consensus includes eight recommendations regarding the criteria for metastasis resection, role of local control treatment in liver potentially resectable patients, management of synchronous liver metastases, approach for peritoneal metastasis, place for resection in multiple-organ metastasis, and general criteria for resectability.

Conclusions: mCRC patients undergoing R0 resection have the greatest survival advantage following surgery. Our role as a multidisciplinary team (MDT) should be to treat potentially resectable mCRC patients as rapidly and safely as possible, and achieve R0 resection as far as possible and for as long as possible (continuum of care). This TSCRS consensus statement aims to help build clinical capacity within the MDTs, while making better use of existing healthcare resources.

Citing Articles

Outcomes of upfront primary tumor resection in patients with synchronous wild-type metastatic colorectal cancer.

Chen P, Chen C, Chang S, Chang Y, Lin B, Chen H Am J Cancer Res. 2025; 14(12):5863-5873.

PMID: 39803657 PMC: 11711521. DOI: 10.62347/DLWI1455.


Survival benefit of metastasectomy in first-line cetuximab therapy in patients with RAS wild-type metastatic colorectal cancer: a nationwide registry.

Chen C, Chang S, Chang Y, Lin B, Chen H, Hsieh Y Am J Cancer Res. 2024; 13(12):6333-6345.

PMID: 38187069 PMC: 10767339.


Carbonic Anhydrase VIII (CAVIII) Gene Mediated Colorectal Cancer Growth and Angiogenesis through Mediated miRNA 16-5p.

Hsieh M, Huang P, Chou P, Wang S, Lu H, Su W Biomedicines. 2022; 10(5).

PMID: 35625769 PMC: 9138292. DOI: 10.3390/biomedicines10051030.


Taiwan Society of Colon and Rectal Surgeons Consensus on mCRC Treatment.

Chen H, Ke T, Huang C, Jiang J, Chen C, Hsieh Y Front Oncol. 2021; 11:764912.

PMID: 34868987 PMC: 8634841. DOI: 10.3389/fonc.2021.764912.


Critical reappraisal of neoadjuvant concurrent chemoradiotherapy for treatment of locally advanced colon cancer.

Chen Y, Tsai H, Li C, Huang C, Chang T, Su W PLoS One. 2021; 16(11):e0259460.

PMID: 34727133 PMC: 8562787. DOI: 10.1371/journal.pone.0259460.


References
1.
Boyle P, Langman J . ABC of colorectal cancer: Epidemiology. BMJ. 2000; 321(7264):805-8. PMC: 1118620. DOI: 10.1136/bmj.321.7264.805. View

2.
Yang L, Parkin D, Li L, Chen Y, Bray F . Estimation and projection of the national profile of cancer mortality in China: 1991-2005. Br J Cancer. 2004; 90(11):2157-66. PMC: 2409509. DOI: 10.1038/sj.bjc.6601813. View

3.
Kumar R, Price T, Beeke C, Jain K, Patel G, Padbury R . Colorectal cancer survival: An analysis of patients with metastatic disease synchronous and metachronous with the primary tumor. Clin Colorectal Cancer. 2013; 13(2):87-93. DOI: 10.1016/j.clcc.2013.11.008. View

4.
Abdalla E, Adam R, Bilchik A, Jaeck D, Vauthey J, Mahvi D . Improving resectability of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol. 2006; 13(10):1271-80. DOI: 10.1245/s10434-006-9045-5. View

5.
Gold J, Are C, Kornprat P, Jarnagin W, Gonen M, Fong Y . Increased use of parenchymal-sparing surgery for bilateral liver metastases from colorectal cancer is associated with improved mortality without change in oncologic outcome: trends in treatment over time in 440 patients. Ann Surg. 2007; 247(1):109-17. DOI: 10.1097/SLA.0b013e3181557e47. View